Tetra Radar · FDA Approvals · Decision date
zipalertinib: FDA decision date
Cullinan Therapeutics, Inc. (CGEM) · 27 February 2027
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
Source: 8-K of 2 October 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.